Assessing Newborn Screening Using Genome Sequencing in France
Official title: A Pilot Study to Assess the Feasibility and Acceptability of Newborn Screening Using in Silico Panel-based Solo Genome Sequencing in France PERIGENOMED-CLINICS 1 (PGC1 Study)
Run by Centre Hospitalier Universitaire Dijon · NCT06875089 · Data updated 2026-11-12
This study is testing whether using genome sequencing for newborn screening in France can be accepted by parents and help identify rare diseases in babies.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 0 Days to 28 Days |
| Sex | All |
| Enrollment | 5000 (estimated) |
| Sponsor | Centre Hospitalier Universitaire Dijon Academic / other |
| Locations | 5 sites (Angers and 4 other locations) |
| Status | Recruiting |
| Started | May 5, 2025 |
| Main results expected | May 2027 |
| Study ends | July 2032 |
| Registry record updated | June 17, 2026 |
| Trial ID | NCT06875089 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include parents or legal guardians of newborns born in participating maternity units who are open to conventional newborn screening.
✕Probably not a fit
Patients who may not benefit include those whose newborns are not born in the participating centers or who object to the use of their data.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This pilot study evaluates the feasibility and acceptability of implementing newborn screening programs based on genome sequencing in France. It aims to gather data from parents and newborns in participating maternity units to understand the potential benefits and challenges of such screening. The study will involve qualitative and quantitative assessments, including satisfaction questionnaires and interviews with healthcare researchers. The goal is to explore how genome sequencing can be integrated into existing newborn screening practices for rare diseases.
Why it matters
Potential benefit: If successful, this study could enhance early detection and intervention for rare diseases in newborns, potentially improving health outcomes.
How similar studies have gone: While similar genome sequencing approaches have shown success in other countries, this specific implementation in France is novel and untested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: For satisfaction study about the information \& identification of determinants of acceptability : Inclusion criteria for parents/legal guardians : * All future parents approached for whom the unborn child will be cared for in the participating maternity unit * At least one parent/legal guardian who received information about the study * Future parents/legal guardian who do not object to the use of their data * Parent(s) or legal guardian(s) affiliated to a social security system or beneficiaries of such a system For pGS-NBS : Inclusion criteria for newborn : * All babies born in one of the participating centers or born by chance outside the maternity but whom care will be carried out in the participating center * Newborn who are less than 28 days at the date of the collection of PGC1 blotting paper Inclusion criteria for parents/legal guardians * At least one biological parent who received information about the study * Parent(s) or legal guardian(s) who do not object to "conventional" NBS * At least one parent/legal guardian able to provide consent for testing the infant * Informed consent signed by at least one parent/legal guardian * Agreement of the second parent/legal guardian for testing the infant (unless he is unknown or loss of contact) obtained from the first parent/legal guardian if his written informed consent has not been obtained * Parent(s) or legal guardian(s) affiliated to a social security system or beneficiaries of such a system Exclusion Criteria: Non inclusion criteria for satisfaction studies and pGS-NBS : Non-inclusion criteria for parents/legal guardians : * Parent(s) or legal guardian(s) under legal protection (guardianship, tutorship) or to a court order Non-inclusion criteria for newborn * Babies born under anonymous birth according to the French law, known as "nés sous X"
Where it's running
-
CHU Dijon Bourgogne
Dijon, France Recruiting -
CHU d'Angers
Angers, France Not yet recruiting -
CHU Besançon
Besançon, France Not yet recruiting -
CHU Hôtel Dieu
Nantes, France Not yet recruiting -
CHU Rennes - Hôpital Sud
Rennes, France Not yet recruiting
Study contacts
- Study coordinator: Laurence OLIVIER-FAIVRE
- Email: laurence.faivre@chu-dijon.fr
- Phone: 0380295313
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Chorioretinal Imaging and Vascular Biomarkers in Ultra-Trail Runners
This study tests whether noninvasive eye imaging can reveal retinal and choroidal blood vessel changes in ultra-trail runners compared with active controls.
-
Lipid and mitochondrial clues in aortic aneurysm with bicuspid or tricuspid valves
This study tests whether inflammatory and metabolic signatures in myeloid cells and aortic tissue differ between patients with bicuspid versus tricuspid aortic valves who need surgery for ascending aortic aneurysm.
-
Value of trio genome sequencing in early-onset and atypical psychiatric disorders
This study tests whether sequencing the genomes of a patient and both biological parents can help explain early-onset or unusual psychiatric disorders in people without intellectual disability or congenital anomalies.
-
Pupillometry to predict postoperative pain after heart surgery
We’re testing whether measuring pupil responses can help predict how much pain a patient will feel after heart surgery once tubes come out and the patient can communicate.
-
BDNF Levels and Atrial Cardiomyopathy in People Having AF Ablation
This study tests whether circulating BDNF levels are linked to atrial cardiomyopathy in adults having their first ablation for persistent atrial fibrillation.
-
Cardiac Amyloidosis: See if Intracardiac Thrombi are Common on CT
This study tests whether a contrast-enhanced cardiac CT can reliably detect intracardiac thrombi in adults with cardiac amyloidosis.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.